

Global RNA Interference (RNAi)-Based Therapeutics Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G5F7FDAF2FA6EN.html>

Date: December 2023

Pages: 106

Price: US\$ 4,480.00 (Single User License)

ID: G5F7FDAF2FA6EN

Abstracts

The global RNA Interference (RNAi)-Based Therapeutics market size is expected to reach \$ 5308.7 million by 2029, rising at a market growth of 26.3% CAGR during the forecast period (2023-2029).

The Small Interfering RNA (siRNA) Drugs Market is driven by the transformative potential of siRNA-based therapies in silencing disease-associated genes, making them a promising approach for treating a wide range of diseases, including genetic disorders, viral infections, and various cancers. siRNA drugs work by selectively degrading or inhibiting the expression of specific genes, offering a highly targeted and personalized treatment option. As the understanding of genomics and RNA interference mechanisms advances, and the need for precision medicine grows, the demand for siRNA drugs continues to rise. Innovations in siRNA design, delivery systems, and gene-editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to overcome delivery barriers, ensure the stability and safety of siRNA therapeutics, and navigate regulatory complexities. Addressing off-target effects, optimizing pharmacokinetics, and managing the high cost of siRNA drug development are ongoing challenges. Additionally, the market faces competition from traditional therapeutic approaches and the need for continuous research and development to unlock the full therapeutic potential of siRNA drugs. Striking a balance between providing safe, effective, and accessible siRNA therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Small Interfering RNA (siRNA) Drugs Market.

This report studies the global RNA Interference (RNAi)-Based Therapeutics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for RNA Interference (RNAi)-Based Therapeutics, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of RNA Interference (RNAi)-Based Therapeutics that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global RNA Interference (RNAi)-Based Therapeutics total market, 2018-2029, (USD Million)

Global RNA Interference (RNAi)-Based Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: RNA Interference (RNAi)-Based Therapeutics total market, key domestic companies and share, (USD Million)

Global RNA Interference (RNAi)-Based Therapeutics revenue by player and market share 2018-2023, (USD Million)

Global RNA Interference (RNAi)-Based Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)

Global RNA Interference (RNAi)-Based Therapeutics total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global RNA Interference (RNAi)-Based Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alnylam, Novartis, Sylentis, Arrowhead, Silence Therapeutics and Dicerna, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World RNA Interference (RNAi)-Based Therapeutics market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global RNA Interference (RNAi)-Based Therapeutics Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global RNA Interference (RNAi)-Based Therapeutics Market, Segmentation by Type

siRNA

miRNA

shRNA

Global RNA Interference (RNAi)-Based Therapeutics Market, Segmentation by Application

AHP

hATTR

Other

Companies Profiled:

Alnylam

Novartis

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Key Questions Answered

1. How big is the global RNA Interference (RNAi)-Based Therapeutics market?
2. What is the demand of the global RNA Interference (RNAi)-Based Therapeutics market?
3. What is the year over year growth of the global RNA Interference (RNAi)-Based Therapeutics market?
4. What is the total value of the global RNA Interference (RNAi)-Based Therapeutics market?
5. Who are the major players in the global RNA Interference (RNAi)-Based Therapeutics market?

Contents

1 SUPPLY SUMMARY

- 1.1 RNA Interference (RNAi)-Based Therapeutics Introduction
- 1.2 World RNA Interference (RNAi)-Based Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World RNA Interference (RNAi)-Based Therapeutics Total Market by Region (by Headquarter Location)
 - 1.3.1 World RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States RNA Interference (RNAi)-Based Therapeutics Market Size (2018-2029)
 - 1.3.3 China RNA Interference (RNAi)-Based Therapeutics Market Size (2018-2029)
 - 1.3.4 Europe RNA Interference (RNAi)-Based Therapeutics Market Size (2018-2029)
 - 1.3.5 Japan RNA Interference (RNAi)-Based Therapeutics Market Size (2018-2029)
 - 1.3.6 South Korea RNA Interference (RNAi)-Based Therapeutics Market Size (2018-2029)
 - 1.3.7 ASEAN RNA Interference (RNAi)-Based Therapeutics Market Size (2018-2029)
 - 1.3.8 India RNA Interference (RNAi)-Based Therapeutics Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 RNA Interference (RNAi)-Based Therapeutics Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 RNA Interference (RNAi)-Based Therapeutics Major Market Trends

2 DEMAND SUMMARY

- 2.1 World RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029)
- 2.2 World RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region
 - 2.2.1 World RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2018-2023)
 - 2.2.2 World RNA Interference (RNAi)-Based Therapeutics Consumption Value Forecast by Region (2024-2029)
- 2.3 United States RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029)
- 2.4 China RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029)
- 2.5 Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value

(2018-2029)

2.6 Japan RNA Interference (RNAi)-Based Therapeutics Consumption Value

(2018-2029)

2.7 South Korea RNA Interference (RNAi)-Based Therapeutics Consumption Value

(2018-2029)

2.8 ASEAN RNA Interference (RNAi)-Based Therapeutics Consumption Value

(2018-2029)

2.9 India RNA Interference (RNAi)-Based Therapeutics Consumption Value

(2018-2029)

3 WORLD RNA INTERFERENCE (RNAI)-BASED THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS

3.1 World RNA Interference (RNAi)-Based Therapeutics Revenue by Player

(2018-2023)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global RNA Interference (RNAi)-Based Therapeutics Industry Rank of Major
Players

3.2.2 Global Concentration Ratios (CR4) for RNA Interference (RNAi)-Based
Therapeutics in 2022

3.2.3 Global Concentration Ratios (CR8) for RNA Interference (RNAi)-Based
Therapeutics in 2022

3.3 RNA Interference (RNAi)-Based Therapeutics Company Evaluation Quadrant

3.4 RNA Interference (RNAi)-Based Therapeutics Market: Overall Company Footprint
Analysis

3.4.1 RNA Interference (RNAi)-Based Therapeutics Market: Region Footprint

3.4.2 RNA Interference (RNAi)-Based Therapeutics Market: Company Product Type
Footprint

3.4.3 RNA Interference (RNAi)-Based Therapeutics Market: Company Product
Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: RNA Interference (RNAi)-Based Therapeutics Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: RNA Interference (RNAi)-Based Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)

4.1.2 United States VS China: RNA Interference (RNAi)-Based Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)

4.2 United States Based Companies VS China Based Companies: RNA Interference (RNAi)-Based Therapeutics Consumption Value Comparison

4.2.1 United States VS China: RNA Interference (RNAi)-Based Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)

4.2.2 United States VS China: RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)

4.3 United States Based RNA Interference (RNAi)-Based Therapeutics Companies and Market Share, 2018-2023

4.3.1 United States Based RNA Interference (RNAi)-Based Therapeutics Companies, Headquarters (States, Country)

4.3.2 United States Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue, (2018-2023)

4.4 China Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue and Market Share, 2018-2023

4.4.1 China Based RNA Interference (RNAi)-Based Therapeutics Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue, (2018-2023)

4.5 Rest of World Based RNA Interference (RNAi)-Based Therapeutics Companies and Market Share, 2018-2023

4.5.1 Rest of World Based RNA Interference (RNAi)-Based Therapeutics Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World RNA Interference (RNAi)-Based Therapeutics Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 siRNA

5.2.2 miRNA

5.2.3 shRNA

5.3 Market Segment by Type

5.3.1 World RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2018-2023)

5.3.2 World RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2024-2029)

5.3.3 World RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World RNA Interference (RNAi)-Based Therapeutics Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 AHP

6.2.2 hATTR

6.2.3 Other

6.3 Market Segment by Application

6.3.1 World RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2018-2023)

6.3.2 World RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2024-2029)

6.3.3 World RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Alnylam

7.1.1 Alnylam Details

7.1.2 Alnylam Major Business

7.1.3 Alnylam RNA Interference (RNAi)-Based Therapeutics Product and Services

7.1.4 Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 Alnylam Recent Developments/Updates

7.1.6 Alnylam Competitive Strengths & Weaknesses

7.2 Novartis

7.2.1 Novartis Details

7.2.2 Novartis Major Business

7.2.3 Novartis RNA Interference (RNAi)-Based Therapeutics Product and Services

7.2.4 Novartis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin

and Market Share (2018-2023)

7.2.5 Novartis Recent Developments/Updates

7.2.6 Novartis Competitive Strengths & Weaknesses

7.3 Sylentis

7.3.1 Sylentis Details

7.3.2 Sylentis Major Business

7.3.3 Sylentis RNA Interference (RNAi)-Based Therapeutics Product and Services

7.3.4 Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Sylentis Recent Developments/Updates

7.3.6 Sylentis Competitive Strengths & Weaknesses

7.4 Arrowhead

7.4.1 Arrowhead Details

7.4.2 Arrowhead Major Business

7.4.3 Arrowhead RNA Interference (RNAi)-Based Therapeutics Product and Services

7.4.4 Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 Arrowhead Recent Developments/Updates

7.4.6 Arrowhead Competitive Strengths & Weaknesses

7.5 Silence Therapeutics

7.5.1 Silence Therapeutics Details

7.5.2 Silence Therapeutics Major Business

7.5.3 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product and Services

7.5.4 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.5.5 Silence Therapeutics Recent Developments/Updates

7.5.6 Silence Therapeutics Competitive Strengths & Weaknesses

7.6 Dicerna

7.6.1 Dicerna Details

7.6.2 Dicerna Major Business

7.6.3 Dicerna RNA Interference (RNAi)-Based Therapeutics Product and Services

7.6.4 Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.6.5 Dicerna Recent Developments/Updates

7.6.6 Dicerna Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 RNA Interference (RNAi)-Based Therapeutics Industry Chain
- 8.2 RNA Interference (RNAi)-Based Therapeutics Upstream Analysis
- 8.3 RNA Interference (RNAi)-Based Therapeutics Midstream Analysis
- 8.4 RNA Interference (RNAi)-Based Therapeutics Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World RNA Interference (RNAi)-Based Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World RNA Interference (RNAi)-Based Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World RNA Interference (RNAi)-Based Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World RNA Interference (RNAi)-Based Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World RNA Interference (RNAi)-Based Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World RNA Interference (RNAi)-Based Therapeutics Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key RNA Interference (RNAi)-Based Therapeutics Players in 2022

Table 12. World RNA Interference (RNAi)-Based Therapeutics Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global RNA Interference (RNAi)-Based Therapeutics Company Evaluation Quadrant

Table 14. Head Office of Key RNA Interference (RNAi)-Based Therapeutics Player

Table 15. RNA Interference (RNAi)-Based Therapeutics Market: Company Product Type Footprint

Table 16. RNA Interference (RNAi)-Based Therapeutics Market: Company Product Application Footprint

Table 17. RNA Interference (RNAi)-Based Therapeutics Mergers & Acquisitions Activity

Table 18. United States VS China RNA Interference (RNAi)-Based Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China RNA Interference (RNAi)-Based Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based RNA Interference (RNAi)-Based Therapeutics Companies, Headquarters (States, Country)

Table 21. United States Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue Market Share (2018-2023)

Table 23. China Based RNA Interference (RNAi)-Based Therapeutics Companies, Headquarters (Province, Country)

Table 24. China Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue Market Share (2018-2023)

Table 26. Rest of World Based RNA Interference (RNAi)-Based Therapeutics Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies RNA Interference (RNAi)-Based Therapeutics Revenue Market Share (2018-2023)

Table 29. World RNA Interference (RNAi)-Based Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2018-2023) & (USD Million)

Table 31. World RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2024-2029) & (USD Million)

Table 32. World RNA Interference (RNAi)-Based Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2018-2023) & (USD Million)

Table 34. World RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2024-2029) & (USD Million)

Table 35. Alnylam Basic Information, Area Served and Competitors

Table 36. Alnylam Major Business

Table 37. Alnylam RNA Interference (RNAi)-Based Therapeutics Product and Services

Table 38. Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Alnylam Recent Developments/Updates

Table 40. Alnylam Competitive Strengths & Weaknesses

Table 41. Novartis Basic Information, Area Served and Competitors

Table 42. Novartis Major Business

Table 43. Novartis RNA Interference (RNAi)-Based Therapeutics Product and Services

Table 44. Novartis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. Novartis Recent Developments/Updates

Table 46. Novartis Competitive Strengths & Weaknesses

Table 47. Sylentis Basic Information, Area Served and Competitors

Table 48. Sylentis Major Business

Table 49. Sylentis RNA Interference (RNAi)-Based Therapeutics Product and Services

Table 50. Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Sylentis Recent Developments/Updates

Table 52. Sylentis Competitive Strengths & Weaknesses

Table 53. Arrowhead Basic Information, Area Served and Competitors

Table 54. Arrowhead Major Business

Table 55. Arrowhead RNA Interference (RNAi)-Based Therapeutics Product and Services

Table 56. Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Arrowhead Recent Developments/Updates

Table 58. Arrowhead Competitive Strengths & Weaknesses

Table 59. Silence Therapeutics Basic Information, Area Served and Competitors

Table 60. Silence Therapeutics Major Business

Table 61. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product and Services

Table 62. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Silence Therapeutics Recent Developments/Updates

Table 64. Dicerna Basic Information, Area Served and Competitors

Table 65. Dicerna Major Business

Table 66. Dicerna RNA Interference (RNAi)-Based Therapeutics Product and Services

Table 67. Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 68. Global Key Players of RNA Interference (RNAi)-Based Therapeutics Upstream (Raw Materials)

Table 69. RNA Interference (RNAi)-Based Therapeutics Typical Customers

LIST OF FIGURE

Figure 1. RNA Interference (RNAi)-Based Therapeutics Picture

Global RNA Interference (RNAi)-Based Therapeutics Supply, Demand and Key Producers, 2023-2029

Figure 2. World RNA Interference (RNAi)-Based Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World RNA Interference (RNAi)-Based Therapeutics Total Market Size (2018-2029) & (USD Million)

Figure 4. World RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company RNA Interference (RNAi)-Based Therapeutics Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company RNA Interference (RNAi)-Based Therapeutics Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company RNA Interference (RNAi)-Based Therapeutics Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company RNA Interference (RNAi)-Based Therapeutics Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company RNA Interference (RNAi)-Based Therapeutics Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company RNA Interference (RNAi)-Based Therapeutics Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company RNA Interference (RNAi)-Based Therapeutics Revenue (2018-2029) & (USD Million)

Figure 13. RNA Interference (RNAi)-Based Therapeutics Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 16. World RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 17. United States RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 18. China RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN RNA Interference (RNAi)-Based Therapeutics Consumption Value

(2018-2029) & (USD Million)

Figure 23. India RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of RNA Interference (RNAi)-Based Therapeutics by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for RNA Interference (RNAi)-Based Therapeutics Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for RNA Interference (RNAi)-Based Therapeutics Markets in 2022

Figure 27. United States VS China: RNA Interference (RNAi)-Based Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World RNA Interference (RNAi)-Based Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type in 2022

Figure 31. siRNA

Figure 32. miRNA

Figure 33. shRNA

Figure 34. World RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2018-2029)

Figure 35. World RNA Interference (RNAi)-Based Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 36. World RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application in 2022

Figure 37. AHP

Figure 38. hATTR

Figure 39. Other

Figure 40. RNA Interference (RNAi)-Based Therapeutics Industrial Chain

Figure 41. Methodology

Figure 42. Research Process and Data Source

I would like to order

Product name: Global RNA Interference (RNAi)-Based Therapeutics Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G5F7FDAF2FA6EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5F7FDAF2FA6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

